This aspect of the direct inhibition of SGLT5 by gliflozins can be relevant when one considers the repurposing of gliflozins to treat the neutropenia caused by deficiencies in G6PC3 and G6PT [3, 4]. This evidence concerns the gene G6PC3 and neutropenia.